GSK has announced a 50/50 joint venture with leading Indian vaccines company, Biological E, for the early stage research and development of a six-in-one combination paediatric vaccine to help ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

The U.S. Food and Drug Administration (FDA) has issued its recommendations to vaccine makers on which virus strains to select when manufacturing influenza (flu) vaccines for the 2025-2026 U.S. flu ...

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

Pertussis Treatment Market Pertussis Medications and Vaccinations Leading Therapeutic Approaches Driving Stance of Companies in the Market: ...

The state-of-the-art biologics facility, acquired by Syngene USA Inc., a wholly owned subsidiary of Syngene, from Emergent ...

while current biologics - including GSK’s IL-5 inhibitor Nucala (mepolizumab) - are restricted to patients with asthma associated with Type 2 (T2) inflammation. GSK is banking on AIO-001 having ...

“The real stroke of brilliance is the notion that you make the cell younger, and then it would be more resilient to injury,” ...